Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin Proline vs sitagliptin for diabetic kidney disease stage 3
ChiCTR2400087971Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of henagliflozin in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Urine albumin-to-creatinine ratio (UACR) and Estimated glomerular filtration rate (eGFR). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR2400087971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087971.